Risk of Fatigue: Atomoxetine vs Qelbree (Viloxazine)
Qelbree (viloxazine) carries a significantly higher risk of fatigue compared to atomoxetine, particularly in adults where fatigue occurs in 12% of Qelbree-treated patients versus 3% on placebo, compared to atomoxetine's less prominent fatigue profile. 1
Comparative Fatigue Risk Profile
Atomoxetine
According to guideline-level evidence, fatigue is listed among the most common adverse effects of atomoxetine in child and adolescent clinical trials, though specific incidence rates are not prominently featured in the safety profile 2. The 2022 Pharmacology and Therapeutics guideline consistently identifies fatigue alongside nausea, vomiting, decreased appetite, abdominal pain, and somnolence as common adverse effects 2.
In adult populations, one study reported fatigue as a treatment-emergent adverse event with atomoxetine, though it was not among the most frequently reported side effects 3.
Qelbree (Viloxazine ER)
The FDA drug label explicitly warns about somnolence and fatigue as a dedicated safety concern (Section 5.4) 1. The specific incidence data from placebo-controlled trials shows:
Pediatric patients (6-17 years):
- Fatigue: 6% on Qelbree vs 2% on placebo (3-fold increase)
- Somnolence: 16% on Qelbree vs 4% on placebo 1
Adult patients (18-60 years):
- Fatigue: 12% on Qelbree vs 3% on placebo (4-fold increase)
- Somnolence: 6% on Qelbree vs 2% on placebo 1
Recent research confirms these findings, with fatigue consistently reported as a common adverse effect across multiple studies 4, 5, 6, 7.
Clinical Implications
Key Differences
- Magnitude of risk: Qelbree demonstrates a quantifiable and substantial increase in fatigue risk over placebo, with adults particularly affected (12% vs 3%)
- FDA recognition: Qelbree carries a specific boxed warning section for somnolence and fatigue, requiring patient counseling about activities requiring mental alertness 1
- Comparative tolerability: In head-to-head comparison, only 4% discontinued Qelbree due to fatigue versus 36% who discontinued atomoxetine for various side effects (including fatigue in 5 patients) 8
Dosing Strategy to Minimize Fatigue
For Qelbree: Evening administration is generally preferable due to the relatively frequent occurrence of somnolence/fatigue 2. The FDA label explicitly states patients should not perform activities requiring mental alertness until they know how they will be affected 1.
For atomoxetine: Can be split into morning and evening doses or administered in the evening only to reduce adverse effects 2.
Important Caveats
- Poor metabolizers: Approximately 7% of the population are poor metabolizers of atomoxetine (via CYP2D6), which significantly increases plasma levels and may amplify adverse effects including fatigue 2
- Onset timing: Atomoxetine's treatment effects take 6-12 weeks to manifest, during which time fatigue may be more prominent during dose titration 2
- Age-related differences: Adults on Qelbree experience double the fatigue rate (12%) compared to pediatric patients (6%) 1
Monitor patients closely during the first few weeks of treatment with either medication, as fatigue may improve with continued use or require dose adjustment or timing modification.